Peritonealdialyse assoziierte Peritonitis

ZUSAMMENFASSUNG

Im Jahr 2022 wurden die neuen Leitlinien der International Society for Peritoneal Dialysis (ISPD) zur Diagnostik, Prophylaxe und Therapie der Peritonitis publiziert. Die maximal tolerierbare Peritonitisrate pro Zentrum wurde auf 0,4 Episoden/ Jahr herabgesenkt, wobei weniger als 15 % der Peritonitisfälle kulturnegativ sein sollten. Es wird empfohlen, auch die Peritonitisfälle, die vor Beginn der Peritonealdialyse (PD) auftreten, separat zu analysieren. Eine antibiotische Prophylaxe wird vor Katheterimplantation sowie vor Kolonoskopien und invasiven gynäkologischen Prozeduren empfohlen. Besondere hygienische Maßnahmen sind erforderlich, wenn Haustiere vorhanden sind. Anstelle einer Kombinationstherapie kann zur Abdeckung des gramnegativen und grampositiven Keimspektrums auch eine Monotherapie mit einem Cephalosporin der 4. Generation verwendet werden. Bei Wahl eines Aminoglykosids wird eine additive Therapie mit N-Azetylcystein zur Verhinderung der Ototoxizität empfohlen. Sollte 48 h nach Therapiebeginn keine Besserung eintreten, müssen weitere diagnostische Maßnahmen wie etwa die Abnahme neuerlicher Kulturen und Computertomografie des Abdomens durchgeführt werden.

Publikationsverlauf

Artikel online veröffentlicht:
31. Mai 2023

• Literatur

• 1 See EJ, Johnson DW, Hawley CM. et al Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. Am J Kidney Dis 2018; 72: 188-197
• 2 Li PK, Chow KM, Cho Y. et al ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42: 110-153
• 3 Ma TK, Chow KM, Kwan BC. et al Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences. Clin J Am Soc Nephrol 2016; 11: 1219-1226
• 4 Crabtree JH, Shrestha BM, Chow KM. et al Creating and Maintaining Optimal Peritoneal Dialysis Access in the Adult Patient: 2019 Update. Perit Dial Int 2019; 39: 414-436
• 5 Li PK, Szeto CC, Piraino B. et al ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Perit Dial Int 2016; 36: 481-508
• 6 Perl J, Fuller DS, Bieber BA. et al Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Am J Kidney Dis 2020; 76: 42-53
• 7 Hu Y, Xu L, Wang X. et al Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study. Int Urol Nephrol 2022; 54: 411-419
• 8 Wikdahl AM, Engman U, Stegmayr BG. et al One-dose cefuroxime i. v. and i. p. reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant 1997; 12: 157-160
• 9 Gadallah MF, Ramdeen G, Mignone J. et al Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am J Kidney Dis 2000; 36: 1014-1019
• 10 Campbell D, Mudge DW, Craig JC. et al Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2017; 04: CD004679
• 11 Szeto CC, Li PK, Johnson DW. et al ISPD Catheter-Related Infection Recommendations: 2017 Update. Perit Dial Int 2017; 37: 141-154
• 12 Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010; 25: 587-592
• 13 Campbell DJ, Brown FG, Craig JC. et al Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. Nephrol Dial Transplant 2016; 31: 619-627
• 14 Lo WK, Chan CY, Cheng SW. et al A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Di. 1996; 28: 549-552
• 15 Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Perit Dial Int 2010; 30: 619-625
• 16 Giacona JM, Weiner M, Hanna J. et al Pasteurella multocida Bacteremia Secondary to Peritoneal Dialysis Associated Peritonitis: A Case Report and Literature Review. Cureus 2022; 14: e24188
• 17 Wu HH, Li IJ, Weng CH. et al Prophylactic antibiotics for endoscopy-associated peritonitis in peritoneal dialysis patients. PloS ONE 2013; 08: e71532
• 18 Fan PY, Chan MJ, Lin SH. et al Prophylactic Antibiotic Reduces the Risk of Peritonitis after Invasive Gynecologic Procedures. Perit Dial Int 2019; 39: 356-361
• 19 Al-Hwiesh AK, Abdul-Rahman IS, Hussameldeen MA. et al Colonoscopy in automated peritoneal dialysis patients: value of prophylactic antibiotics: a prospective study on a single antibiotic. Int J Artif Organs 2017; 40: 550-557
• 20 Oka H, Tsuruya K, Nakano T. Prophylactic Oral Antibiotics for Postendoscopic Peritonitis in Peritoneal Dialysis. Ther Apher Dial 2020; 24: 462-463
• 21 Chan GC, Wong SH, Ng JK. et al Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Perit Dial Int 2022; 42: 162-170
• 22 Chow KM, Szeto CC, Law MC. et al Influence of peritoneal dialysis training nurses’ experience on peritonitis rates. Clin J Am Soc Nephrol 2007; 02: 647-652
• 23 Cheetham MS, Zhao J, McCullough K. et al International peritoneal dialysis training practices and the risk of peritonitis. Nephrol Dial Transplant 2022; 37: 937-949
• 24 Dong J, Chen Y. Impact of the bag exchange procedure on risk of peritonitis. Perit Dial Int 2010; 30: 440-447
• 25 Chang JH, Oh J, Park SK. et al Frequent patient retraining at home reduces the risks of peritoneal dialysis-related infections: A randomised study. Sci Rep 2018; 08: 12919
• 26 Xu Y, Zhang Y, Yang B. et al Prevention of peritoneal dialysis-related peritonitis by regular patient retraining via technique inspection or oral education: a randomized controlled trial. Nephrol Dial Transplant 2020; 35: 676-686
• 27 Chuang YW, Shu KH, Yu TM. et al Hypokalaemia: an independent risk factor of Enterobacteriaceae peritonitis in CAPD patients. Nephrol Dial Transplant 2009; 24: 1603-1608
• 28 Shu KH, Chang CS, Chuang YW. et al Intestinal bacterial overgrowth in CAPD patients with hypokalaemia. Nephrol Dial Transplant 2009; 24: 1289-1292
• 29 Pichitporn W, Kanjanabuch T, Phannajit J. et al Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. Am J Kidney Dis 2022; 80: 580-588
• 30 Kitrungphaiboon T, Puapatanakul P, Chuengsaman P. et al Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial. Am J Kidney Dis 2019; 74: 601-609
• 31 Kocyigit I, Vural A, Unal A. et al Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Eur Arch Otorhinolaryngol 2015; 272: 2611-2620
• 32 Tokgoz B, Ucar C, Kocyigit I. et al Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transplant 2011; 26: 4073-4078
• 33 Vural A, Kocyigit I, San F. et al Long-Term Protective Effect of N-Acetylcysteine against Amikacin-Induced Ototoxicity in End-Stage Renal Disease: A Randomized Trial. Perit Dial Int 2018; 38: 57-62